DaVita Financials - Benzinga

DaVita Inc

DVANYSE

Trade with Public

Trade with Public

$182.34

-1.52-0.83%

$182.34

N/A

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

DaVita Financials

DaVita (DVA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
DaVita Affirms FY2026 Adj EPS Guidance of $14.10-$15.20 vs $14.82 Est

DaVita (NYSE:DVA) affirms FY2026 Adj EPS guidance from $14.10-$15.20 to $14.10-$15.20 vs $14.82 analyst estimate..

Benzinga Newsdesk

PRO
DaVita Q2 Adj. EPS $4.02 Beats $3.88 Estimate, Sales $3.554B Beat $3.496B Estimate

DaVita (NYSE:DVA) reported quarterly earnings of $4.02 per share which beat the analyst consensus estimate of $3.88 by 3.61 percent. This is a 36.27 percent increase over earnings of $2.95 per share from the same period

Benzinga Newsdesk

PRO
DaVita Raises FY2026 Adj EPS Guidance from $13.60-$15.00 to $14.10-$15.20 vs $13.98 Est

DaVita (NYSE:DVA) raises FY2026 Adj EPS guidance from $13.60-$15.00 to $14.10-$15.20 vs $13.98 analyst estimate..

Benzinga Newsdesk

PRO
DaVita Q1 Adj. EPS $2.87 Beats $2.32 Estimate, Sales $3.416B Beat $3.356B Estimate

DaVita (NYSE:DVA) reported quarterly earnings of $2.87 per share which beat the analyst consensus estimate of $2.32 by 23.71 percent. This is a 43.5 percent increase over earnings of $2.00 per share from the same period

Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights

DaVita Stock Rallies On Profit Beat, Confident 2026 View

DaVita stock surged after the kidney care provider beat earnings estimates and issued strong 2026 guidance, signaling stable treatment volumes, higher reimbursement rates, and an improving income outlook.

Vandana Singh